Advertisement
AZTA vs TMO
Which Stock Would AI Choose? Azenta, Inc. (AZTA) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- AZTA, a niche player in life sciences sample management, has rebounded in recent weeks from 52-week lows, offering higher potential upside with analyst targets around $36 from current levels.
- TMO demonstrates stability as a diversified life sciences giant with a market cap over $195 billion and consistent profitability (15% profit margins).
- AZTA's higher beta (1.47) signals greater volatility compared to TMO's 0.97, appealing to risk-tolerant traders.
- Recent market activity highlights AZTA's sensitivity to semiconductor and biotech spending, while TMO benefits from broad diagnostics demand and partnerships.
- Year-to-date, AZTA has outperformed with +20% gains versus TMO's more modest returns, amid relative performance shifts.
- Valuation contrasts: AZTA trades below book value, while TMO commands a premium for scale and growth.
Introduction
This stock comparison pits AZTA (Azenta, Inc.), a specialized provider of automation and sample management solutions for life sciences and semiconductors, against TMO (Thermo Fisher Scientific Inc.), a diversified leader in analytical instruments, diagnostics, and biopharma services. Both operate in the healthcare equipment and life sciences sector, benefiting from biotech innovation and research demand. Traders seeking high-growth niche plays may eye AZTA, while long-term investors favoring stability and scale might prefer TMO. This analysis examines recent performance, business drivers, and relative positioning to inform stock comparison decisions in today's market environment.
AZTA Overview and Recent Performance
Azenta, Inc. (AZTA) delivers sample management solutions and multiomics services, including automated storage systems, cryogenic equipment, gene sequencing, and synthesis for life sciences and semiconductor clients. With a market cap of approximately $1.2 billion, it focuses on high-precision tools amid biotech R&D and chip manufacturing cycles. Recent market activity reveals volatility, with shares rebounding from 52-week lows near $20 in late March 2026 to around $26, driven by semiconductor demand recovery and life sciences spending. A first-quarter earnings miss earlier in the year pressured sentiment, but year-to-date gains exceed 20%, reflecting optimism in growth segments despite negative profit margins (-10%) and a high beta of 1.47. Analyst targets average $36, signaling potential upside from transitional challenges.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is a global powerhouse with $44.6 billion in trailing revenue, spanning life sciences solutions, analytical instruments, specialty diagnostics, and laboratory services. Its scale (market cap $195 billion) supports robust profitability (15% margins, ROE 13%) across diverse markets like pharmaceuticals and clinical labs. In recent weeks, shares have traded steadily around $526, down from 52-week highs near $644 but up modestly amid anticipation for Q1 2026 earnings on April 23. Positive sentiment stems from partnerships in proteomics and data alliances, alongside consistent revenue growth (7% quarterly), though higher debt/equity (77%) reflects acquisition strategy. A beta of 0.97 underscores lower volatility, with analyst targets near $648.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto, selecting only those best suited to current market conditions based on real-time adaptability. These bots showcase impressive ranges: annualized returns from +15% to +168%, win rates of 54% to 88%, profit factors up to 11.7, and drawdowns managed with profit-to-drawdown ratios exceeding 20 in top cases. Strategies vary from swing trading and trend following to volatility plays with 2x/3x leveraged ETFs, targeting sectors like semiconductors and industrials. Diverse timeframes (1 day to 55 days) cater to different styles. Investors can explore these high-performing bots to enhance their trading edge in dynamic markets.
Head-to-Head Comparison
AZTA and TMO both serve life sciences but differ sharply in scale and focus: AZTA's niche in sample automation and multiomics exposes it to biotech R&D cycles and semiconductor fab needs, while TMO's diversified model spans diagnostics and biopharma services for steadier growth. Momentum favors AZTA's recent rebound versus TMO's consolidation, but TMO leads in profitability and revenue scale. Risk trade-offs include AZTA's losses and high beta against TMO's leverage. Sector exposure overlaps in healthcare equipment, yet TMO benefits from broader diagnostics tailwinds. Market sentiment tilts positive for both, with AZTA offering value (P/S 1.93) and TMO premium positioning (P/S 4.5).
Tickeron AI Verdict
Tickeron's AI currently favors TMO over AZTA, citing superior trend consistency, profitability, lower volatility (beta 0.97), and catalysts like upcoming earnings and partnerships. While AZTA shows rebound momentum and undervaluation, TMO's scale and stability position it better for sustained outperformance in the near term, probabilistically weighted by observable factors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTA is a StrongBuy and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTA’s FA Score shows that 0 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- AZTA’s FA Score: 0 green, 5 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTA’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- AZTA’s TA Score: 4 bullish, 6 bearish.
- TMO’s TA Score: 3 bullish, 7 bearish.
Price Growth
AZTA (@Pharmaceuticals: Other) experienced а +1.06% price change this week, while TMO (@Medical Specialties) price change was +0.97% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +15.04%. For the same industry, the average monthly price growth was +13.60%, and the average quarterly price growth was -9.42%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.10%. For the same industry, the average monthly price growth was +10.03%, and the average quarterly price growth was -1.01%.
Reported Earning Dates
AZTA is expected to report earnings on Aug 11, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+15.04% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+2.10% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| AZTA | TMO | AZTA / TMO | |
| Capitalization | 1.06B | 176B | 1% |
| EBITDA | 36.6M | 11.7B | 0% |
| Gain YTD | -30.998 | -18.084 | 171% |
| P/E Ratio | 42.43 | 26.04 | 163% |
| Revenue | 596M | 45.2B | 1% |
| Total Cash | 381M | 1.12B | 34% |
| Total Debt | 55.7M | 43.2B | 0% |
AZTA | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 92 | |
SMR RATING 1..100 | 95 | 62 | |
PRICE GROWTH RATING 1..100 | 49 | 53 | |
P/E GROWTH RATING 1..100 | 87 | 44 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is somewhat better than the same rating for AZTA (52) in the Electronic Production Equipment industry. This means that TMO’s stock grew somewhat faster than AZTA’s over the last 12 months.
TMO's Profit vs Risk Rating (92) in the Medical Specialties industry is in the same range as AZTA (100) in the Electronic Production Equipment industry. This means that TMO’s stock grew similarly to AZTA’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is somewhat better than the same rating for AZTA (95) in the Electronic Production Equipment industry. This means that TMO’s stock grew somewhat faster than AZTA’s over the last 12 months.
AZTA's Price Growth Rating (49) in the Electronic Production Equipment industry is in the same range as TMO (53) in the Medical Specialties industry. This means that AZTA’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (44) in the Medical Specialties industry is somewhat better than the same rating for AZTA (87) in the Electronic Production Equipment industry. This means that TMO’s stock grew somewhat faster than AZTA’s over the last 12 months.
| AZTA | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 52% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 47% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 60% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 70% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 61% |
| Advances ODDS (%) | 1 day ago 70% | 16 days ago 62% |
| Declines ODDS (%) | 12 days ago 82% | 5 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 47% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 62% |
Advertisement
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.